Pregnancy and primary pulmonary hypertension : successful outcome with epoprostenol therapy

Chest. 2001 Mar;119(3):973-5. doi: 10.1378/chest.119.3.973.


Primary pulmonary hypertension (PPH) associated with pregnancy carries a high maternal mortality rate. Short-term epoprostenol infusion has been demonstrated to improve the hemodynamic profile in patients with PPH. We report a successful maternal-fetal outcome with epoprostenol therapy during pregnancy, cesarean section, and postpartum in a patient with PPH. Epoprostenol therapy did not produce any physical or developmental abnormalities in the fetus. A favorable maternal-fetal outcome may occur with a multidisciplinary approach.

MeSH terms

  • Adult
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / therapeutic use*
  • Epoprostenol / administration & dosage
  • Epoprostenol / therapeutic use*
  • Female
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / drug therapy*
  • Pregnancy Outcome
  • Treatment Outcome


  • Antihypertensive Agents
  • Epoprostenol